UK
Natalie Rush
I bring more than 25 years of experience helping pharmaceutical and biotech companies optimize trade, distribution, and customer engagement strategies. My focus is on designing evidence-driven solutions that streamline distribution, enhance patient access, and strengthen relationships across the healthcare ecosystem. Throughout my career, I’ve led initiatives that transform complex distribution models into efficient, patient-centric systems. My expertise spans specialty pharmacy, wholesale distribution, alternative channel and integrated delivery networks, enabling clients to navigate evolving market dynamics while improving operational performance and patient outcomes.
Before joining LCP, I served as Principal of Specialty Consulting at EVERSANA, where I advised leading pharmaceutical and biotech organizations on trade relations, channel strategy, and distribution optimization. My work centered on aligning commercial objectives with innovative access solutions to ensure therapies reach patients quickly and effectively.
I’m passionate about leveraging data-driven strategies to create sustainable models that benefit manufacturers, providers, and patients alike. My approach combines strategic insight with practical execution, making me a trusted advisor for clients seeking to maximize market access and deliver measurable impact.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Reimagining patient services: The transformative role of Artificial Intelligence and Intelligent Automation in US market access
Explore how AI and IA are transforming US Patient Support Programs by reducing manual workload, streamlining access processes, and improving time-to-therapy.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
